目的：探讨依托考昔和美洛昔康在治疗膝骨关节炎中的可行性。方法选取我院2014年3月～2014年12月收治的100例膝骨关节炎患者进行研究，将其随机分为研究组和对照组，对照组给予美洛昔康治疗，研究组给予依托考昔治疗，比较两组患者Womac关节炎指数、严重程度指数及临床疗效。结果对照组有效率为74.00%，研究组为92.00%，组间比较差异有统计学意义（P＜0.05）。治疗前两组患者Womac关节炎指数及严重程度指数组间对比差异无统计学意义（P＞0.05），经过治疗后均有明显降低，较治疗前比较差异均有统计学意义（P＜0.05）。在治疗1周及3周后研究组患者Womac关节炎指数和严重程度指数均较对照组低，差异有统计学意义（P＜0.05）。结论与美洛昔康相比，依托考昔在治疗膝骨关节炎时起效速度更快，对膝骨关节炎的临床症状改善效果更佳，值得在临床治疗中推广应用。%Objective To evaluate the feasibility of etoricoxib and meloxicam in treatment of knee osteoarthritis. Methods100 cases of patients with knee osteoarthritis from March 2014 to December 2014 were chosen to research,and were divided into experimental and control group,experimental group was treated with etoricoxib,control group was treated with meloxicam,Womac osteoarthritis index,severity index and curative effects between two group were compared.Results The curative rate of control group was 74.00%,while the experimental group was 92.00%,there were statistically significant differences between groups (P<0.05).Womac osteoarthritis index and severity index between two group had no significant statistical difference before treatment,and were all decreased obviously after treatment,with great statistical difference comparing to before(P<0.05).Womac osteoarthritis index and severity index of experimental group were lower than that of the control group after 1 and 3 weeks' treatments,difference were statistically significant(P<0.05).Conclusion Compared with meloxicam,etoricoxib has quicker speed of onset in treatment of knee osteoarthritis,and better clinical symptoms improved better effect,worth be application in clinical treatment.
展开▼
